Prior research found that older adults with CKD, heart failure, and cardiovascular disease are less likely to fill SGLT-2 medications than those of younger age and those without such comorbid conditions, despite well documented clinical benefits [26]. Here, SLC5A2 is linked to chronic kidney disease.